ZA200303729B - Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. - Google Patents

Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. Download PDF

Info

Publication number
ZA200303729B
ZA200303729B ZA200303729A ZA200303729A ZA200303729B ZA 200303729 B ZA200303729 B ZA 200303729B ZA 200303729 A ZA200303729 A ZA 200303729A ZA 200303729 A ZA200303729 A ZA 200303729A ZA 200303729 B ZA200303729 B ZA 200303729B
Authority
ZA
South Africa
Prior art keywords
compound
receptor
agonists
pharmaceutical composition
antagonists
Prior art date
Application number
ZA200303729A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Bryan Mckibben
David J Witter
Original Assignee
Osi Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Application filed by Osi Pharmaceutical Inc filed Critical Osi Pharmaceutical Inc
Publication of ZA200303729B publication Critical patent/ZA200303729B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200303729A 2000-12-01 2003-05-14 Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. ZA200303729B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof

Publications (1)

Publication Number Publication Date
ZA200303729B true ZA200303729B (en) 2004-05-14

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200303729A ZA200303729B (en) 2000-12-01 2003-05-14 Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof.

Country Status (20)

Country Link
EP (1) EP1347980A4 (cs)
JP (1) JP4579497B2 (cs)
CN (1) CN1263757C (cs)
AP (1) AP1893A (cs)
AU (1) AU2002248151B2 (cs)
BR (1) BR0115847A (cs)
CA (1) CA2430577A1 (cs)
CZ (1) CZ20031831A3 (cs)
EA (1) EA007254B1 (cs)
HU (1) HUP0400692A3 (cs)
IL (1) IL155962A0 (cs)
ME (1) MEP35308A (cs)
MX (1) MXPA03004717A (cs)
NO (1) NO327207B1 (cs)
NZ (1) NZ525885A (cs)
OA (1) OA13295A (cs)
PL (1) PL363245A1 (cs)
WO (1) WO2002057267A1 (cs)
YU (1) YU42703A (cs)
ZA (1) ZA200303729B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
EA003604B1 (ru) 1998-06-02 2003-06-26 Оси Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
MXPA04005510A (es) * 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
AU2002366811B2 (en) 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
US7199119B2 (en) * 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ES2344800T3 (es) * 2005-02-18 2010-09-07 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y diureticos.
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
MX2010007523A (es) 2008-01-11 2010-08-18 Natco Pharma Ltd Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
JP6080837B2 (ja) 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
PL2785349T5 (pl) 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RU2014151004A (ru) * 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
NZ754629A (en) 2013-06-21 2021-07-30 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
EP3010917B1 (en) * 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
MX380276B (es) * 2015-01-20 2025-03-12 Wuxy Fortune Pharmaceutical Co Ltd Inhibidor jak.
CN107531695B (zh) 2015-04-29 2020-03-27 无锡福祈制药有限公司 Jak抑制剂
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN105771672B (zh) * 2016-04-18 2018-03-02 天津工业大学 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
EP3594216B1 (en) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
CN118834214A (zh) * 2018-06-04 2024-10-25 爱克思科技有限公司 作为腺苷受体拮抗剂的吡唑并嘧啶化合物
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
EA003604B1 (ru) * 1998-06-02 2003-06-26 Оси Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ
PT1246623E (pt) * 1999-12-02 2006-12-29 Osi Pharm Inc Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
JP2005529062A (ja) * 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用

Also Published As

Publication number Publication date
CN1489590A (zh) 2004-04-14
JP4579497B2 (ja) 2010-11-10
AU2002248151B2 (en) 2008-02-21
CN1263757C (zh) 2006-07-12
EA007254B1 (ru) 2006-08-25
PL363245A1 (en) 2004-11-15
EA200300628A1 (ru) 2003-12-25
NO327207B1 (no) 2009-05-11
MXPA03004717A (es) 2004-06-30
NO20032482L (no) 2003-07-28
HUP0400692A3 (en) 2007-09-28
EP1347980A1 (en) 2003-10-01
WO2002057267A1 (en) 2002-07-25
OA13295A (en) 2007-04-13
JP2004517896A (ja) 2004-06-17
EP1347980A4 (en) 2005-02-09
MEP35308A (en) 2011-02-10
NZ525885A (en) 2005-01-28
HUP0400692A2 (hu) 2004-07-28
BR0115847A (pt) 2004-02-25
YU42703A (sh) 2006-03-03
AP1893A (en) 2008-09-23
AP2003002807A0 (en) 2003-06-30
CZ20031831A3 (cs) 2004-05-12
IL155962A0 (en) 2003-12-23
CA2430577A1 (en) 2002-07-25
NO20032482D0 (no) 2003-06-02

Similar Documents

Publication Publication Date Title
ZA200303729B (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof.
KR100840727B1 (ko) 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US6770666B2 (en) Fused-ring compounds and use thereof as drugs
JP4611524B2 (ja) ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6664252B2 (en) 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US20040082635A1 (en) Fused cyclic compounds and medicinal use thereof
AU757290B2 (en) Imidazolone anorectic agents: II. phenyl derivatives
CA2468673C (en) Compounds specific to adenosine a1 and a3 receptors and uses thereof
AU2002248151A1 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
EP1162196A1 (en) Fused-ring compounds and use thereof as drugs
KR20070072598A (ko) 인돌 및 벤지미다졸 유도체
KR100395356B1 (ko) 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노인돌 화합물
JPH08333363A (ja) インドール誘導体
JP2003505376A (ja) ベンズイミダゾロン誘導体およびそのホスホジエステラーゼ阻害剤としての用途
EP1513589B1 (en) 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
CN102985425A (zh) 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途
JPH07258221A (ja) ベンゾイミダゾール、これらの化合物を含む医薬組成物及びそれらの調製方法
JP2009519988A (ja) アデノシンａ３受容体モジュレーターとしてのピロロ［１，２−ａ］キノキサリン誘導体およびその使用
EP3271334A1 (de) Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung
JP3204456B2 (ja) ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
NZ263614A (en) Pharmaceutical use of 5-(methylaminosulphonylmethyl)-3- (n-methylpyrrolidin-2-ylmethyl)-1h-indole and of the corresponding -3-(pyrrolidin-2-ylmethyl)-derivative
KR20010032435A (ko) 5-(2-이미다졸리닐아미노)벤즈이미다졸 유도체, 그의 제조및 대사 안정성이 개선된 알파-아드레날린수용체아고니스트로서의 그의 용도
JP2003212846A (ja) 縮合環化合物及びｃ型肝炎治療剤
CZ394492A3 (en) Benzimidazole derivatives, process of their preparation and pharmaceutical preparations in which said derivatives are comprised
WO2024155601A1 (en) Compounds, compositions and methods of use to treat hypoparathyroidism and osteoporosis